HR 1143
Medicare IVIG Access Enhancement Act of 2025
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill aims to improve Medicare coverage for intravenous immune globulin (IVIG) administered in patients’ homes. Specifically, it expands Medicare coverage to include treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, two types of autoimmune conditions. The bill allows for variances in payments based on whether the IVIG treatment is related to primary immune deficiency diseases or these specific neurological conditions, as determined by the Secretary of Health and Human Services.
Key provisions
- Medicare will cover in-home administration of IVIG.
- Coverage will be expanded to include treatment for CIDP and multifocal motor neuropathy.
- The coverage expansion will begin on January 1, 2027.
- The Secretary of Health and Human Services will have the authority to determine when variances in payments are appropriate.
- Payment variances will be based on whether the IVIG treatment is for primary immune deficiency diseases or CIDP/multifocal motor neuropathy.
Who is affected
- Medicare beneficiaries
- Individuals with CIDP
- Individuals with multifocal motor neuropathy
- Healthcare providers administering IVIG
Notable changes
- Adds CIDP and multifocal motor neuropathy to the list of conditions covered by Medicare IVIG.
- Allows for payment variances based on the specific condition being treated.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 1st Session
H. R. 1143
IN THE HOUSE OF REPRESENTATIVES
A BILL
To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.
This Act may be cited as the Medicare IVIG Access Enhancement Act of 2025
.
in subsection (s)(2)(Z), by inserting (and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)
after primary immune deficiency diseases
; and
in subsection (zz), by inserting (or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)
after primary immune deficiency disease
.
and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)after
of 2012.